HYAL AT2101

Drug Profile

HYAL AT2101

Alternative Names: Diclofenac + HA topical; Hyaluronic acid + diclofenac; Hyanalgese-D; Oralease

Latest Information Update: 11 Dec 2007

Price : $50

At a glance

  • Originator SkyePharma Inc
  • Developer Pacira Pharmaceuticals; SkyePharma Inc; Symbion Health
  • Class Glycosaminoglycans; Nonsteroidal anti-inflammatories; Phenylacetates
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Aphthous ulcer pain; Pain; Rheumatic disorders

Most Recent Events

  • 08 Dec 1998 Phase-III clinical trials for Aphthous ulcer pain in USA (Topical)
  • 01 Oct 1998 Hyal Pharmaceutical has acquired the rights to HYAL AT2101 in Asian countries, which had been licensed to its Australian subsidiary
  • 12 Feb 1998 Discontinued-III for Pain in Czech Republic (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top